Reviva Pharmaceuticals Holdings (RVPH) Payables (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Payables of $2.3 million for Q1 2026, down 32.18% sequentially from $3.4 million in Q4 2025, and down 53.16% YoY from $4.9 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Payables (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Payables for 9 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Payables fell 53.16% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 53.16% YoY) and the FY2025 annual result came in at $3.4 million, down 49.33% from the prior year.
- Payables declined to $2.3 million in Q1 2026 per RVPH's latest filing, from $3.4 million in the prior quarter.
- Over five years, Payables peaked at $8.9 million in Q3 2024 and troughed at $1.4 million in Q1 2022.
- A 5-year average of $4.3 million and a median of $3.8 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2026: Payables soared 612.68% in 2022, then plunged 53.16% in 2026.
- Over 5 years, Payables stood at $3.5 million in 2022, then gained by 9.34% to $3.8 million in 2023, then soared by 75.15% to $6.7 million in 2024, then slumped by 49.33% to $3.4 million in 2025, then slumped by 32.18% to $2.3 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $2.3 million, $3.4 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 35.57 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.40 Mn | 6.40 Mn | - | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | 3.42 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | 5.08 Mn |
| Mar 31, 2025 | 4.95 Mn |
| Dec 31, 2024 | 6.74 Mn |
| Sep 30, 2024 | 8.86 Mn |
| Jun 30, 2024 | 4.90 Mn |
| Mar 31, 2024 | 6.05 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Sep 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 2.87 Mn |
| Mar 31, 2023 | 3.53 Mn |
| Dec 31, 2022 | 3.52 Mn |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 1.43 Mn |
| Sep 30, 2021 | 420,783.00 |
| Jun 30, 2021 | 358,257.00 |